Susquehanna International Group
FENC icon

Susquehanna International Group’s Fennec Pharmaceuticals FENC Stock Holding History

Susquehanna International Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,023
Closed -$159K – 12709
2025
Q3 		$159K Sell
17,023
-29,828
-64% -$258K ﹤0.01% 11228
2025
Q2 		$389K Buy
46,851
+16,593
+55% +$114K ﹤0.01% 9758
2025
Q1 		$184K Buy
30,258
+17,826
+143% +$114K ﹤0.01% 11026
2024
Q4 		$78.6K Buy
+12,432
New +$63.7K ﹤0.01% 11475
2024
Q2 		– Sell
-22,599
Closed -$251K – 12355
2024
Q1 		$251K Buy
22,599
+7,559
+50% +$75.9K ﹤0.01% 10109
2023
Q4 		$169K Buy
+15,040
New +$125K ﹤0.01% 10857
2023
Q3 		– Sell
-11,429
Closed -$93K – 12277
2023
Q2 		$101K Sell
11,429
-149,891
-93% -$1.25M ﹤0.01% 10941
2023
Q1 		$1.34M Buy
161,320
+53,707
+50% +$498K ﹤0.01% 6080
2022
Q4 		$1.03M Buy
+107,613
New +$952K ﹤0.01% 6109
2022
Q3 		– Sell
-49,075
Closed -$337K – 13450
2022
Q2 		$277K Sell
49,075
-84,889
-63% -$493K ﹤0.01% 9780
2022
Q1 		$750K Sell
133,964
-137
-0.1% -$690 ﹤0.01% 7889
2021
Q4 		$590K Buy
134,101
+107,159
+398% +$798K ﹤0.01% 8735
2021
Q3 		$254K Buy
26,942
+12,544
+87% +$94.1K ﹤0.01% 10976
2021
Q2 		$105K Buy
+14,398
New +$96.1K ﹤0.01% 12073
2021
Q1 		– Sell
-11,368
Closed -$85K – 12407
2020
Q4 		$85K Sell
11,368
-21,492
-65% -$164K ﹤0.01% 10576
2020
Q3 		$199K Sell
32,860
-126,088
-79% -$889K ﹤0.01% 9459
2020
Q2 		$1.33M Buy
158,948
+70,430
+80% +$524K ﹤0.01% 5294
2020
Q1 		$526K Buy
88,518
+31,742
+56% +$207K ﹤0.01% 6833
2019
Q4 		$368K Buy
56,776
+34,736
+158% +$187K ﹤0.01% 7599
2019
Q3 		$106K Buy
+22,040
New +$97.3K ﹤0.01% 9535
2018
Q2 		– Sell
-56,707
Closed -$686K – 9827
2018
Q1 		$686K Buy
+56,707
New +$536K ﹤0.01% 6000

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Susquehanna International Group's FENC Position: Q4 2025 in Review

Susquehanna International Group sold out of Fennec Pharmaceuticals (FENC) in Q4 2025, closing a stake of 17,023 shares — an estimated $159K sold.

Susquehanna International Group first reported a position in FENC in Q1 2018 and held it in 21 quarters. The position peaked at $1.34M in Q1 2023. 96 funds tracked by Wall St. Rank hold FENC as of Q4 2025.

  • Susquehanna International Group reported no remaining Fennec Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 17,023 Fennec Pharmaceuticals shares in Q4 2025, an estimated $159K.
  • Susquehanna International Group first reported a position in Fennec Pharmaceuticals in Q1 2018 and held it in 21 quarters.
  • Susquehanna International Group's Fennec Pharmaceuticals position peaked at $1.34M in Q1 2023.
  • 96 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.